Figure 6: Effect of HMGB1 and ATM on Cardiac Hypertrophic Signaling

(A, B) Representative images and analysis Western blots of phospho-extracellular signal-related kinase 1/2 (p-ERK1/2), total ERK1/2 (t-ERK1/2), phospho-nuclear factor kappa B (p-NF-κB), and total NF-κB (t-NF-κB) from NRCMs transfected with pcDNA-HMGB1 or control vector and then treated with saline or Ang II for 4 h (n = 6 per group). (C, D) Representative images and analysis of Western blots of p-ERK1/2, t-ERK1/2, p-NF-κB, and t-NF-κB from NRCMs transfected with siHMGB1 or nonspecific control siRNA and then treated with saline or Ang II for 4 h (n = 6 per group). (E) Representative Western blots of p-ERK1/2, t-ERK1/2, p-NF-κB, and t-NF-κB. NRCMs transfected with siHMGB1 or nonspecific control siRNA were pretreated with an ATM inhibitor (KU55933) or dimethyl sulfoxide (DMSO) for 1 h before Ang II stimulation, and then stimulated with saline or Ang II for 4 h. (F, G) Quantification of atrial natriuretic peptide (ANP) and BNP promoter activities. Rat H9C2 cells were pretreated with an ATM inhibitor (KU55933) or DMSO for 1 h before Ang II stimulation, and then stimulated with saline or Ang II for 24 h (n = 6 per group). Results are presented as the mean ± SE. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. Abbreviations as in Figures 1, 2, 3, 4, and 5.